CytokineticsCYTK
CYTK
About: Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Employees: 564
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
82% more call options, than puts
Call options by funds: $278M | Put options by funds: $152M
47% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 96
0% more funds holding
Funds holding: 343 [Q2] → 343 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 46
3% less capital invested
Capital invested by funds: $7.4B [Q2] → $7.15B (-$250M) [Q3]
12.33% less ownership
Funds ownership: 130.25% [Q2] → 117.92% (-12.33%) [Q3]
25% less funds holding in top 10
Funds holding in top 10: 20 [Q2] → 15 (-5) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$72
48%
upside
Avg. target
$94
94%
upside
High target
$120
147%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 22% 1-year accuracy 86 / 386 met price target | 147%upside $120 | Buy Reiterated | 23 Dec 2024 |
RBC Capital Leonid Timashev 41% 1-year accuracy 18 / 44 met price target | 69%upside $82 | Outperform Maintained | 18 Dec 2024 |
Needham Serge Belanger 40% 1-year accuracy 50 / 126 met price target | 48%upside $72 | Buy Reiterated | 2 Dec 2024 |
Mizuho Salim Syed 40% 1-year accuracy 8 / 20 met price target | 112%upside $103 | Outperform Maintained | 21 Nov 2024 |
Financial journalist opinion
Based on 10 articles about CYTK published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).
Positive
The Motley Fool
6 days ago
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index.
Neutral
GlobeNewsWire
6 days ago
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM.
Negative
Zacks Investment Research
2 weeks ago
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Negative
Zacks Investment Research
3 weeks ago
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
Neutral
GlobeNewsWire
3 weeks ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 29, 2024 it granted stock options to purchase an aggregate of 34,515 shares of common stock and 22,410 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced in November 2024, as a material inducement to their employment.
Positive
Zacks Investment Research
3 weeks ago
FDA Accepts Cytokinetics' Application for Cardiovascular Drug
CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.
Neutral
GlobeNewsWire
3 weeks ago
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF (Confirmation of O mecamtiv M ecarbil Efficacy Trial in Heart Failure), a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure (HF) with severely reduced ejection fraction, is open to enrollment. Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator in development for the potential treatment of heart failure with severely reduced ejection fraction. COMET-HF is being conducted in collaboration with Duke Clinical Research Institute (DCRI), a leading academic research organization.
Neutral
GlobeNewsWire
3 weeks ago
Cytokinetics to Participate in December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following December investor conferences:
Neutral
GlobeNewsWire
3 weeks ago
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
PDUFA Target Action Date Set for September 26, 2025 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM).
Charts implemented using Lightweight Charts™